BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8934608)

  • 1. Cardiovascular effects of oral hypoglycaemic drugs.
    Howes LG; Sundaresan P; Lykos D
    Clin Exp Pharmacol Physiol; 1996 Mar; 23(3):201-6. PubMed ID: 8934608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK; Carson DS; Bjelajac A
    J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral hypoglycemic agents.
    Ferner RE
    Med Clin North Am; 1988 Nov; 72(6):1323-35. PubMed ID: 3054355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma HDL in non-insulin-dependent diabetes and the effect of various types of treatment.
    Shoukry M; Jayyab AK
    Atherosclerosis; 1983 Dec; 49(3):333-8. PubMed ID: 6661271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
    Fisman EZ; Motro M; Tenenbaum A
    Adv Cardiol; 2008; 45():154-170. PubMed ID: 18230961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biguanides and sulfonylureas as combination therapy in NIDDM.
    Hermann LS
    Diabetes Care; 1990 Aug; 13 Suppl 3():37-41. PubMed ID: 2209342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
    Marchetti P; Navalesi R
    Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
    Loubatiéres A; Mariani MM; Ribes G; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
    [No Abstract]   [Full Text] [Related]  

  • 12. The sulfonylurea controversy: more questions from the heart.
    Brady PA; Terzic A
    J Am Coll Cardiol; 1998 Apr; 31(5):950-6. PubMed ID: 9561992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of oral hypoglycaemic agents in the treatment of diabetes mellitus.
    Larkins RG
    Med J Aust; 1987 May; 146(9):477-80. PubMed ID: 3302638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into antidiabetic drugs: Possible applications in cancer treatment.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Zarghami N
    Chem Biol Drug Des; 2017 Dec; 90(6):1056-1066. PubMed ID: 28456998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
    Mannucci E; Monami M; Masotti G; Marchionni N
    Diabetes Metab Res Rev; 2004; 20(1):44-7. PubMed ID: 14737744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemic and anti-hyperglycaemic drugs for the control of diabetes.
    Bailey CJ
    Proc Nutr Soc; 1991 Dec; 50(3):619-30. PubMed ID: 1809970
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
    Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG
    Diabetes Care; 1997 May; 20(5):692-7. PubMed ID: 9135928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of metformin in the treatment of type 2 diabetes mellitus.
    Davidson MB; Peters AL
    Am J Med; 1997 Jan; 102(1):99-110. PubMed ID: 9209206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.